Jump to content

Mathias Uhlén: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Docenterna (talk | contribs)
114 edits
mNo edit summary
Docenterna (talk | contribs)
114 edits
Rewrote and updated the page
Line 53: Line 53:
}}
}}


'''Mathias Uhlén''' (born May 1954) is a Swedish scientist, [[biotechnology|biotechnologist]], and Professor of Microbiology at [[Royal Institute of Technology|Royal Institute of Technology (KTH)]], Stockholm.<ref name="kth">{{cite web|title=Mathias Uhlén|url=https://www.kth.se/pro/sysbio/uhlen-group/researchers|website=School of Engineering Sciences in Chemistry, Biotechnology and Health}}</ref> His research interests cover [[Monoclonal antibody|antibody engineering]], [[proteomics]] and [[precision medicine]].<ref name="kth"/>
'''Mathias Uhlén''' (born May 1954) is a Swedish scientis and Professor of Microbiology at [[Royal Institute of Technology|Royal Institute of Technology (KTH)]], Stockholm.<ref name="kth">{{cite web|title=Mathias Uhlén|url=https://www.kth.se/pro/sysbio/uhlen-group/researchers|website=School of Engineering Sciences in Chemistry, Biotechnology and Health}}</ref> After a post-doc period at the [[European Molecular Biology Laboratory|EMBL]] in Heidelberg, Germany, he became professor in [[microbiology]] at KTH in 1988. His research is focused on protein science, [[antibody engineering]] and [[Personalized medicine|precision medicine]] and range from basic research in human and microbial biology to more applied research, including clinical applications. His research has led to more than 750 publications and more than 90,000 citations.<ref>{{Google Scholar id|id=S8ER7X4AAAAJ}}</ref>. He is member of several academies and societies, including [[Royal Swedish Academy of Sciences|Royal Swedish Academy of Science (KVA)]], [[National Academy of Engineering|National Academy of Engineering (NAE)]] and the [[Royal Swedish Academy of Engineering Sciences|Swedish Academy of Engineering Science (IVA)]]


==Life==
== Research ==
IHis group was the first to describe a number of innovations in science including:
In 1984 Uhlén received his PhD at the [[Royal Institute of Technology|Royal Institute of Technology (KTH)]] in Stockholm. After being employed at the [[European Molecular Biology Laboratory]] in [[Heidelberg]], Germany, he became professor at KTH in 1988. His research has led to more than 750 publications, 80,000 citations.<ref>{{Google Scholar id | id= S8ER7X4AAAAJ}}</ref>


1.     '''Affinity-based [[protein engineering]]'''. This broad concept was developed to use specific binding ([[Ligand (biochemistry)#Receptor.2Fligand binding affinity|affinity]]) of proteins in combination with protein engineering and it has led to many successful applications widely used in the life science community. This includes (A) engineered [[protein A]]<ref>{{Cite journal |last=Uhlén |first=M. |last2=Guss |first2=B. |last3=Nilsson |first3=B. |last4=Gatenbeck |first4=S. |last5=Philipson |first5=L. |last6=Lindberg |first6=M. |date=1984-02-10 |title=Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications |url=https://pubmed.ncbi.nlm.nih.gov/6319407 |journal=The Journal of Biological Chemistry |volume=259 |issue=3 |pages=1695–1702 |issn=0021-9258 |pmid=6319407}}</ref> and [[protein G]] for purification of antibodies (B) [[Protein tag|affinity tags]] <ref>{{Cite journal |last=Löwenadler |first=B |last2=Nilsson |first2=B |last3=Abrahmsén |first3=L |last4=Moks |first4=T |last5=Ljungqvist |first5=L |last6=Holmgren |first6=E |last7=Paleus |first7=S |last8=Josephson |first8=S |last9=Philipson |first9=L |last10=Uhlén |first10=M |date=1986-09 |title=Production of specific antibodies against protein A fusion proteins. |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1167125/ |journal=The EMBO Journal |volume=5 |issue=9 |pages=2393–2398 |doi=10.1002/j.1460-2075.1986.tb04509.x |issn=0261-4189 |pmc=1167125 |pmid=3096719}}</ref> for purification of recombinant [[Fusion protein|fusion proteins]] (C) [[Affibody molecule|Affibodies]] <ref>{{Cite journal |last=Nord |first=Karin |last2=Gunneriusson |first2=Elin |last3=Ringdahl |first3=Jenny |last4=Ståhl |first4=Stefan |last5=Uhlén |first5=Mathias |last6=Nygren |first6=Per-Åke |date=1997-08 |title=Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain |url=http://www.nature.com/articles/nbt0897-772 |journal=Nature Biotechnology |language=en |volume=15 |issue=8 |pages=772–777 |doi=10.1038/nbt0897-772 |issn=1087-0156}}</ref> – clinically validated protein scaffold binders (D) the first solid phase methods for DNA handling using the [[biotin]] - [[streptavidin]] system <ref>{{Cite journal |last=Uhlen |first=M. |date=1989-08 |title=Magnetic separation of DNA |url=http://www.nature.com/articles/340733a0 |journal=Nature |language=en |volume=340 |issue=6236 |pages=733–734 |doi=10.1038/340733a0 |issn=0028-0836}}</ref> and (E) MabSelect SuRe – alkali-stabled matrix for purification of antibodies. This ligand has been used for the manufacturing of the majority of [[therapeutic antibodies]] on the market today.
In 2003, as part of an international project to map the complete human proteome and transcriptome system, the [[Human Protein Atlas]] project was created and launched. Uhlén is Program Director of the project. There are six additional projects within the primary project.
* The Tissue Atlas<ref>{{cite journal | vauthors = Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F | display-authors = 1 | author-link1 = Mathias Uhlén | title = Proteomics. Tissue-based map of the human proteome | journal = Science | volume = 347 | issue = 6220 | pages = 1260419 | date = 2015 | pmid = 25613900 | doi = 10.1126/science.1260419 | s2cid = 802377 }}</ref> is a Swedish project to provide expression profiles of human genes both on the mRNA and protein level, within the body.
* The Cell Atlas<ref name="pmid28495876">{{cite journal | vauthors = Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, Bäckström A, Danielsson F, Fagerberg L, Fall J, Gatto L, Gnann C, Hober S, Hjelmare M, Johansson F, Lee S, Lindskog C, Mulder J, Mulvey CM, Nilsson P, Oksvold P, Rockberg J, Schutten R, Schwenk JM, Sivertsson Å, Sjöstedt E, Skogs M, Stadler C, Sullivan DP, Tegel H, Winsnes C, Zhang C, Zwahlen M, Mardinoglu A, Pontén F, von Feilitzen K, Lilley KS, Uhlén M, Lundberg E | display-authors = 1 | title = A subcellular map of the human proteome | journal = Science | volume = 356 | issue = 6340 | pages = eaal3321| date = 2017 | pmid = 28495876 | doi = 10.1126/science.aal3321 | s2cid = 10744558 }}</ref> provides high-resolution insights into the spatial distribution of proteins within cells.
* The Pathology Atlas<ref name="pmid28818916">{{cite journal | vauthors = Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F | display-authors = 1 | title = A pathology atlas of the human cancer transcriptome | journal = Science | volume = 357 | issue = 6352 | pages = eaan2507| date = 2017 | pmid = 28818916 | doi = 10.1126/science.aan2507 | doi-access = free | s2cid = 206659235 }}</ref> showing how cancer patient survival is tied to RNA and protein levels. The project contains [[Messenger RNA|mRNA]] and protein expression data for the most common forms of human cancer.
* The Blood Atlas<ref name="pmid=31857451">{{cite journal |last1=Uhlen |first1=M |last2=Karlsson |first2=MJ |last3=Zhong |first3=W |last4=Tebani |first4=A |last5=Pou |first5=C |last6=Mikes |first6=J |last7=Lakshmikanth |first7=T |last8=Forsström |first8=B |last9=Edfors |first9=F |last10=Odeberg |first10=J |last11=Mardinoglu |first11=A |last12=Zhang |first12=C |last13=von Feilitzen |first13=K |last14=Mulder |first14=J |last15=Sjöstedt |first15=E |last16=Hober |first16=A |last17=Oksvold |first17=P |last18=Zwahlen |first18=M |last19=Ponten |first19=F |last20=Lindskog |first20=C |last21=Sivertsson |first21=Å |last22=Fagerberg |first22=L |last23=Brodin |first23=P | display-authors = 1 |title=A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. |journal=Science |date=2019 |volume=366 |issue=6472 | pages=eaax9198 | doi=10.1126/science.aax9198 | pmid=31857451|s2cid=209424418 }}</ref> showing the expression of proteins in human immune cells and also mapping the proteins in human blood
* The Brain Atlas<ref>{{cite journal |last1=Sjöstedt |first1=E |last2=Zhong |first2=W |last3=Fagerberg |first3=L |last4=Karlsson |first4=M |last5=Mitsios |first5=N |last6=Adori |first6=C |last7=Oksvold |first7=P |last8=Edfors |first8=F |last9=Limiszewska |first9=A |last10=Hikmet |first10=F |last11=Huang |first11=J |last12=Du |first12=Y |last13=Lin |first13=L |last14=Dong |first14=Z |last15=Yang |first15=L |last16=Liu |first16=X |last17=Jiang |first17=H |last18=Xu |first18=X |last19=Wang |first19=J |last20=Yang |first20=H |last21=Bolund |first21=L |last22=Mardinoglu |first22=A |last23=Zhang |first23=C |last24=von Feilitzen |first24=K |last25=Lindskog |first25=C |last26=Pontén |first26=F |last27=Luo |first27=Y |last28=Hökfelt |first28=T |last29=Uhlén |first29=M |last30=Mulder |first30=J | display-authors = 1|title=An atlas of the protein-coding genes in the human, pig, and mouse brain. |journal=Science |date=2020 |volume=367 |issue=6482 |pages=eaay5947 |doi=10.1126/science.aay5947 |pmid=32139519|s2cid=212560645 }}</ref> showing the proteins expressed in the different parts of human, pig and mouse brains.
* The Single Cell Type Atlas shows single cell RNA sequencing (scRNAseq) data from 13 different human tissues, together with immunohistochemically stained tissue sections visualizing the corresponding spatial protein expression patterns.


2.     '''Real-time sequencing by synthesis.''' This concept involves the detecting of the incorporation of nucleotides in real-time during synthesis by a [[DNA polymerase]] and to use this for [[DNA sequencing]].  The concept, first described in 1993 <ref>{{Cite journal |last=Nyren |first=P. |last2=Pettersson |first2=B. |last3=Uhlen |first3=M. |date=1993-01 |title=Solid Phase DNA Minisequencing by an Enzymatic Luminometric Inorganic Pyrophosphate Detection Assay |url=https://linkinghub.elsevier.com/retrieve/pii/S0003269783710249 |journal=Analytical Biochemistry |language=en |volume=208 |issue=1 |pages=171–175 |doi=10.1006/abio.1993.1024}}</ref>, depends on several important underlying technologies, including attachment of [[Solid phase sequencing|DNA to solid supports]], the use of engineered polymerases for synthesis a complementary [[nucleotide]] and the detection of the incorporated nucleotide to generate sequencing. This was used by the [[Pyrosequencing]] <ref>{{Cite journal |last=Ronaghi |first=Mostafa |last2=Uhlén |first2=Mathias |last3=Nyrén |first3=Pål |date=1998-07-17 |title=A Sequencing Method Based on Real-Time Pyrophosphate |url=https://www.science.org/doi/10.1126/science.281.5375.363 |journal=Science |language=en |volume=281 |issue=5375 |pages=363–365 |doi=10.1126/science.281.5375.363 |issn=0036-8075}}</ref> method leading to the first [[massive parallel sequencing]] instrument ([[454 Life Sciences|454]]). The concept of real time sequencing by synthesis is now used in all major “next generation sequencing” systems.
==Awards and honours==


3.     '''Map of the human proteome'''. The Human Protein Atlas program started in 2003 with the aim to contribute to the holistic understanding of all the proteins encoded from our DNA. The objective of the program is to map all the human proteins in cells, tissues, and organs using integration of various omics technologies, including antibody-based [[Microscopy|imaging]], [[mass spectrometry]]-based [[proteomics]], [[Transcriptomics technologies|transcriptomics]], and [[systems biology]]. The ultimate aim for the project is a complete understanding of the functions and interactions of all proteins and where in the different cells and tissues they reside. During the first 20 years, the open access resource has launched more than 5 million web pages with 10 million high-resolution microscope images, to allow individual researchers both in industry and academia to explore the proteome space across the human body.  The resource consists of various sections, spanning from tissues<ref name=":0">{{Cite journal |last=Uhlén |first=Mathias |last2=Fagerberg |first2=Linn |last3=Hallström |first3=Björn M. |last4=Lindskog |first4=Cecilia |last5=Oksvold |first5=Per |last6=Mardinoglu |first6=Adil |last7=Sivertsson |first7=Åsa |last8=Kampf |first8=Caroline |last9=Sjöstedt |first9=Evelina |last10=Asplund |first10=Anna |last11=Olsson |first11=IngMarie |last12=Edlund |first12=Karolina |last13=Lundberg |first13=Emma |last14=Navani |first14=Sanjay |last15=Szigyarto |first15=Cristina Al-Khalili |date=2015-01-23 |title=Tissue-based map of the human proteome |url=https://www.science.org/doi/10.1126/science.1260419 |journal=Science |language=en |volume=347 |issue=6220 |pages=1260419 |doi=10.1126/science.1260419 |issn=0036-8075}}</ref>, brain<ref>{{Cite journal |last=Sjöstedt |first=Evelina |last2=Zhong |first2=Wen |last3=Fagerberg |first3=Linn |last4=Karlsson |first4=Max |last5=Mitsios |first5=Nicholas |last6=Adori |first6=Csaba |last7=Oksvold |first7=Per |last8=Edfors |first8=Fredrik |last9=Limiszewska |first9=Agnieszka |last10=Hikmet |first10=Feria |last11=Huang |first11=Jinrong |last12=Du |first12=Yutao |last13=Lin |first13=Lin |last14=Dong |first14=Zhanying |last15=Yang |first15=Ling |date=2020-03-06 |title=An atlas of the protein-coding genes in the human, pig, and mouse brain |url=https://www.science.org/doi/10.1126/science.aay5947 |journal=Science |language=en |volume=367 |issue=6482 |pages=eaay5947 |doi=10.1126/science.aay5947 |issn=0036-8075}}</ref>, immune cells <ref>{{Cite journal |last=Uhlen |first=Mathias |last2=Karlsson |first2=Max J. |last3=Zhong |first3=Wen |last4=Tebani |first4=Abdellah |last5=Pou |first5=Christian |last6=Mikes |first6=Jaromir |last7=Lakshmikanth |first7=Tadepally |last8=Forsström |first8=Björn |last9=Edfors |first9=Fredrik |last10=Odeberg |first10=Jacob |last11=Mardinoglu |first11=Adil |last12=Zhang |first12=Cheng |last13=von Feilitzen |first13=Kalle |last14=Mulder |first14=Jan |last15=Sjöstedt |first15=Evelina |date=2019-12-20 |title=A genome-wide transcriptomic analysis of protein-coding genes in human blood cells |url=https://www.science.org/doi/10.1126/science.aax9198 |journal=Science |language=en |volume=366 |issue=6472 |pages=eaax9198 |doi=10.1126/science.aax9198 |issn=0036-8075}}</ref> , blood proteins, diseases and structures. The Tissue Atlas paper <ref name=":0" />,is one of the most cited publications from Europe in the last 10 years.
He is member of the


== Science for Life Laboratory (SciLifeLab) ==
* [[National Academy of Engineering|National Academy of Engineering (NAE)]]<ref>{{cite web|title=2013 Annual Report|url=https://www.nae.edu/File.aspx?id=115393|website=National Academy of Engineering|publisher=NAE|accessdate=17 January 2018|format=pdf|date=2013}}</ref> in USA, the [[Royal_Swedish_Academy_of_Sciences|Royal Swedish Academy of Science (KVA)]].
Dr Uhlen was the Founding Director of the [[Science for Life Laboratory|SciLifeLab]] from 2010-2015. This national infrastructure was launched in Stockholm with funding from the Swedish government to allow technology- and data-driven research to be establish as a support for Swedish and European research in life science. From 2013, the infrastructure was merged with a similar center in Uppsala. Many thousands of projects are executed annually, spanning many research fields, such as genomics, proteomics, structural biology, planetary biology, data-driven life science, drug development and precision medicine.
* [[Royal Swedish Academy of Engineering Sciences|Royal Academy of Engineering Sciences (IVA)]]<ref>{{cite web|title=Mathias Uhlén|url=http://www.kva.se/en/om-oss/kontakt/mathias-uhlen|website=The Royal Swedish Academy of Sciences|publisher=The Royal Swedish Academy of Sciences|accessdate=17 January 2018}}</ref>
* [[European Molecular Biology Organization|European Molecular Biology Organization (EMBO)]].<ref>{{cite web|title=Mathias Uhlén|url=https://people.embo.org/profile/mathias-uhlen|website=EMBO People directory|publisher=Gesellschaft zur Förderung der Lebenswissenschaften Heidelberg GmbH|accessdate=17 January 2018}}</ref>


== Career ==
He is the President of the [[European Federation of Biotechnology]]. From 2010 to 2015, he was the founding Director of the [[Science for Life Laboratory|Science for Life Laboratory (SciLifeLab)]] which is a national center for molecular bioscience.
1979                M.Sc. in Chemical Engineering, KTH, Stockholm, Sweden.

1984                Ph.D. Dept. of Biotechnology, KTH, Stockholm, Sweden

1985-86           Post-doc, [[European Molecular Biology Laboratory|EMBL]], Heidelberg, Germany

1988-               Full professor in Biotechnology, KTH, Stockholm, Sweden

1999-2001       Vice-President KTH, responsible for external relations

2003-               Director of the [[Human Protein Atlas|Human Protein Atlas (HPA)]] program

2010-2015       Founding Director, [[Science for Life Laboratory|Science for Life Laboratory (SciLifeLab)]]

2012-2020       Professor (20%), [[Technical University of Denmark|Danish Technical University (DTU)]], Denmark

2019-               Guest professor (25%) at Karolinska Institutet

2019-               Member of the Board of Directors for the Swedish Research Council

== Recognition ==

* Member of the [[National Academy of Engineering|National Academy of Engineering (NAE)]], USA, 2013-
* Member of the [[Royal Swedish Academy of Sciences|Royal Swedish Academy of Science (KVA)]], 1993-
* Member of the [[Royal Swedish Academy of Engineering Sciences|Swedish Academy of Engineering Science (IVA)]], 1992-
* Member of [[European Molecular Biology Organization|European Molecular Biology Organization (EMBO)]], 1995-
* President of the [[European Federation of Biotechnology|European Federation Biotechnology (EFB)]], 2014-2020
* Chairman of the [[UniProt|Scientific Advisory Board of UniProt]], 2013-2016
* [[Royal Swedish Academy of Engineering Sciences|IVA]] Gold Medal, 2003, from the Royal Academy of Engineering Sciences
* [https://stiftelsemedel.se/stiftelsen-akzo-nobel-science-award-sweden/ Arthur D. Little Nordic Life Science Award], 2004
* [[H. M. The King's Medal|H.M. The King's Medal, 2004, from His Majesty the King of Sweden]]
* [https://stiftelsemedel.se/stiftelsen-akzo-nobel-science-award-sweden/ AKZO Nobel Science Award] in 2005
* [[Human Proteome Organization|HUPO]] Distinguished Award, Long Beach, USA, 2006 from HUPO
* [[:sv:KTH:s_stora_pris|KTH Great Prize]] in 2006
* The Scheele Prize<ref>{{Citation |title=Scheelepriset |date=2022-05-06 |url=https://sv.wikipedia.org/w/index.php?title=Scheelepriset&oldid=50452179 |work=Wikipedia |access-date=2023-04-01 |language=sv}}</ref> in 2007
* [[Association of Biomolecular Resource Facilities|ABRF]] Award from the Assoc. Biomolecular Resources Facilities in 2009
* Honorary Doctor, [[Chalmers University of Technology|Chalmers University]], Gothenburg in 2011
* Honorary Doctor, Rouen University, France in 2020

== Entrepeneurial achievements (selected) ==
Member of several Board of Directors, including public companies such as [[Bure Equity|Bure]]  (Sweden), Biotage <ref>{{Cite web |last=Biotage |title=Biotage: Drug Discovery, Analytical, Water and Environmental testing |url=https://www.biotage.com/ |access-date=2023-04-01 |website=www.biotage.com |language=en}}</ref> (Sweden), Alligator Bioscience <ref>{{Cite web |title=Alligator Bioscience – Tumor-directed immunotherapy of cancer |url=https://alligatorbioscience.se/en/ |access-date=2023-04-01 |website=alligatorbioscience.se |language=en-US}}</ref> (Sweden), [[Novozymes]] (Denmark) and [[Amersham plc|Amersham]] (UK).


== References ==
== References ==
Line 80: Line 114:


==External links==
==External links==
* {{Google Scholar id | id= S8ER7X4AAAAJ}}
* {{Google Scholar id | id= S8ER7X4AAAAJ}} or ORCID https://orcid.org/0000-0002-4858-8056
{{authority control}}
{{authority control}}


Revision as of 15:39, 1 April 2023

Mathias Uhlén
EducationRoyal Institute of Technology, European Molecular Biology Laboratory
Scientific career
FieldsChemistry
Biology
Microbiology
Biotechnology
Biomedicine
InstitutionsRoyal Institute of Technology
Danish Technical University
Karolinska Institutet

Mathias Uhlén (born May 1954) is a Swedish scientis and Professor of Microbiology at Royal Institute of Technology (KTH), Stockholm.[1] After a post-doc period at the EMBL in Heidelberg, Germany, he became professor in microbiology at KTH in 1988. His research is focused on protein science, antibody engineering and precision medicine and range from basic research in human and microbial biology to more applied research, including clinical applications. His research has led to more than 750 publications and more than 90,000 citations.[2]. He is member of several academies and societies, including Royal Swedish Academy of Science (KVA), National Academy of Engineering (NAE) and the Swedish Academy of Engineering Science (IVA)

Research

IHis group was the first to describe a number of innovations in science including:

1.     Affinity-based protein engineering. This broad concept was developed to use specific binding (affinity) of proteins in combination with protein engineering and it has led to many successful applications widely used in the life science community. This includes (A) engineered protein A[3] and protein G for purification of antibodies (B) affinity tags [4] for purification of recombinant fusion proteins (C) Affibodies [5] – clinically validated protein scaffold binders (D) the first solid phase methods for DNA handling using the biotin - streptavidin system [6] and (E) MabSelect SuRe – alkali-stabled matrix for purification of antibodies. This ligand has been used for the manufacturing of the majority of therapeutic antibodies on the market today.

2.     Real-time sequencing by synthesis. This concept involves the detecting of the incorporation of nucleotides in real-time during synthesis by a DNA polymerase and to use this for DNA sequencing.  The concept, first described in 1993 [7], depends on several important underlying technologies, including attachment of DNA to solid supports, the use of engineered polymerases for synthesis a complementary nucleotide and the detection of the incorporated nucleotide to generate sequencing. This was used by the Pyrosequencing [8] method leading to the first massive parallel sequencing instrument (454). The concept of real time sequencing by synthesis is now used in all major “next generation sequencing” systems.

3.     Map of the human proteome. The Human Protein Atlas program started in 2003 with the aim to contribute to the holistic understanding of all the proteins encoded from our DNA. The objective of the program is to map all the human proteins in cells, tissues, and organs using integration of various omics technologies, including antibody-based imaging, mass spectrometry-based proteomics, transcriptomics, and systems biology. The ultimate aim for the project is a complete understanding of the functions and interactions of all proteins and where in the different cells and tissues they reside. During the first 20 years, the open access resource has launched more than 5 million web pages with 10 million high-resolution microscope images, to allow individual researchers both in industry and academia to explore the proteome space across the human body.  The resource consists of various sections, spanning from tissues[9], brain[10], immune cells [11] , blood proteins, diseases and structures. The Tissue Atlas paper [9],is one of the most cited publications from Europe in the last 10 years.

Science for Life Laboratory (SciLifeLab)

Dr Uhlen was the Founding Director of the SciLifeLab from 2010-2015. This national infrastructure was launched in Stockholm with funding from the Swedish government to allow technology- and data-driven research to be establish as a support for Swedish and European research in life science. From 2013, the infrastructure was merged with a similar center in Uppsala. Many thousands of projects are executed annually, spanning many research fields, such as genomics, proteomics, structural biology, planetary biology, data-driven life science, drug development and precision medicine.

Career

1979                M.Sc. in Chemical Engineering, KTH, Stockholm, Sweden.

1984                Ph.D. Dept. of Biotechnology, KTH, Stockholm, Sweden

1985-86           Post-doc, EMBL, Heidelberg, Germany

1988-               Full professor in Biotechnology, KTH, Stockholm, Sweden

1999-2001       Vice-President KTH, responsible for external relations

2003-               Director of the Human Protein Atlas (HPA) program

2010-2015       Founding Director, Science for Life Laboratory (SciLifeLab)

2012-2020       Professor (20%), Danish Technical University (DTU), Denmark

2019-               Guest professor (25%) at Karolinska Institutet

2019-               Member of the Board of Directors for the Swedish Research Council

Recognition

Entrepeneurial achievements (selected)

Member of several Board of Directors, including public companies such as Bure  (Sweden), Biotage [13] (Sweden), Alligator Bioscience [14] (Sweden), Novozymes (Denmark) and Amersham (UK).

References

  1. ^ "Mathias Uhlén". School of Engineering Sciences in Chemistry, Biotechnology and Health.
  2. ^ Mathias Uhlén publications indexed by Google Scholar
  3. ^ Uhlén, M.; Guss, B.; Nilsson, B.; Gatenbeck, S.; Philipson, L.; Lindberg, M. (1984-02-10). "Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications". The Journal of Biological Chemistry. 259 (3): 1695–1702. ISSN 0021-9258. PMID 6319407.
  4. ^ Löwenadler, B; Nilsson, B; Abrahmsén, L; Moks, T; Ljungqvist, L; Holmgren, E; Paleus, S; Josephson, S; Philipson, L; Uhlén, M (1986-09). "Production of specific antibodies against protein A fusion proteins". The EMBO Journal. 5 (9): 2393–2398. doi:10.1002/j.1460-2075.1986.tb04509.x. ISSN 0261-4189. PMC 1167125. PMID 3096719. {{cite journal}}: Check date values in: |date= (help)
  5. ^ Nord, Karin; Gunneriusson, Elin; Ringdahl, Jenny; Ståhl, Stefan; Uhlén, Mathias; Nygren, Per-Åke (1997-08). "Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain". Nature Biotechnology. 15 (8): 772–777. doi:10.1038/nbt0897-772. ISSN 1087-0156. {{cite journal}}: Check date values in: |date= (help)
  6. ^ Uhlen, M. (1989-08). "Magnetic separation of DNA". Nature. 340 (6236): 733–734. doi:10.1038/340733a0. ISSN 0028-0836. {{cite journal}}: Check date values in: |date= (help)
  7. ^ Nyren, P.; Pettersson, B.; Uhlen, M. (1993-01). "Solid Phase DNA Minisequencing by an Enzymatic Luminometric Inorganic Pyrophosphate Detection Assay". Analytical Biochemistry. 208 (1): 171–175. doi:10.1006/abio.1993.1024. {{cite journal}}: Check date values in: |date= (help)
  8. ^ Ronaghi, Mostafa; Uhlén, Mathias; Nyrén, Pål (1998-07-17). "A Sequencing Method Based on Real-Time Pyrophosphate". Science. 281 (5375): 363–365. doi:10.1126/science.281.5375.363. ISSN 0036-8075.
  9. ^ a b Uhlén, Mathias; Fagerberg, Linn; Hallström, Björn M.; Lindskog, Cecilia; Oksvold, Per; Mardinoglu, Adil; Sivertsson, Åsa; Kampf, Caroline; Sjöstedt, Evelina; Asplund, Anna; Olsson, IngMarie; Edlund, Karolina; Lundberg, Emma; Navani, Sanjay; Szigyarto, Cristina Al-Khalili (2015-01-23). "Tissue-based map of the human proteome". Science. 347 (6220): 1260419. doi:10.1126/science.1260419. ISSN 0036-8075.
  10. ^ Sjöstedt, Evelina; Zhong, Wen; Fagerberg, Linn; Karlsson, Max; Mitsios, Nicholas; Adori, Csaba; Oksvold, Per; Edfors, Fredrik; Limiszewska, Agnieszka; Hikmet, Feria; Huang, Jinrong; Du, Yutao; Lin, Lin; Dong, Zhanying; Yang, Ling (2020-03-06). "An atlas of the protein-coding genes in the human, pig, and mouse brain". Science. 367 (6482): eaay5947. doi:10.1126/science.aay5947. ISSN 0036-8075.
  11. ^ Uhlen, Mathias; Karlsson, Max J.; Zhong, Wen; Tebani, Abdellah; Pou, Christian; Mikes, Jaromir; Lakshmikanth, Tadepally; Forsström, Björn; Edfors, Fredrik; Odeberg, Jacob; Mardinoglu, Adil; Zhang, Cheng; von Feilitzen, Kalle; Mulder, Jan; Sjöstedt, Evelina (2019-12-20). "A genome-wide transcriptomic analysis of protein-coding genes in human blood cells". Science. 366 (6472): eaax9198. doi:10.1126/science.aax9198. ISSN 0036-8075.
  12. ^ "Scheelepriset", Wikipedia (in Swedish), 2022-05-06, retrieved 2023-04-01
  13. ^ Biotage. "Biotage: Drug Discovery, Analytical, Water and Environmental testing". www.biotage.com. Retrieved 2023-04-01.
  14. ^ "Alligator Bioscience – Tumor-directed immunotherapy of cancer". alligatorbioscience.se. Retrieved 2023-04-01.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Mathias_Uhlén&oldid=1147692881"